Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-yearWeekly multi-patient prescribers grew ...

Tarsus to Participate in Upcoming Investor Conference

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the ...

Tarsus outlines $140M–$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress

Management expects Q4 XDEMVY net product sales in the range of $140 million to $145 million, with annual revenue guidance at $440 million to $445 million. Farrow added, "We also expect inventory ...
Medscape

Ocular Rosacea Underappreciated in Dermatology and Beyond

For ocular rosacea, dermatologists can do more than hand off patients to ophthalmology by asking the right questions and ...
TipRanks on MSN

Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth

Tarsus Pharmaceuticals, Inc. ( ($TARS) ) has released its Q3 earnings. Here is a breakdown of the information Tarsus Pharmaceuticals, Inc.
newscase

Tarsus Pharmaceuticals Faces Critical Earnings Test

All eyes are on Tarsus Pharmaceuticals Inc as the company prepares to release its quarterly earnings after market close today ...
Ophthalmology Times

Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5

Opus Genetics has completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the US Food and Drug ...
Ophthalmology Times

Balancing Anti-VEGF and GA Therapies for Co-Treating AMD and GA in the Same Eye

An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and ...